Elanco’s Pradalex draws attention to targeted BRD treatment
Livestock health | United States | Autumn–winter 2026
As cattle producers prepare for colder weather and associated management challenges, Elanco’s Pradalex (pradofloxacin injection) is being highlighted as a treatment option for specified cases of bovine respiratory disease (BRD). The product is a prescription veterinary antimicrobial whose use is restricted by its US label.
Pradalex is not a newly introduced molecule in the sense of a first-time approval in 2026: its US prescribing information was already available before the current autumn reporting period. The latest coverage should therefore be understood as renewed seasonal attention to BRD prevention and treatment, rather than a claim of a new approval this week. Sources: Elanco product technical manual and DailyMed label.
What is Pradalex?
Pradalex contains 200 mg of pradofloxacin per millilitre of injectable solution. Pradofloxacin is a fluoroquinolone antimicrobial.
According to the US label, the product is indicated for treatment of BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis in specified cattle classes. The label defines which beef and young breeding cattle may be treated and excludes certain categories, including cows and breeding cattle aged one year or older, beef calves younger than two months, dairy calves and veal calves.
The precise label is decisive: the product is not approved for unrestricted use across all cattle classes or all respiratory disease presentations.
Why BRD remains a major production challenge
Bovine respiratory disease is a complex syndrome involving interactions among infectious agents, host immunity, transport and handling stress, environmental conditions, stocking density and management. Cold weather can compound risk where ventilation is inadequate, animals are crowded or temperature changes coincide with transport and other stressors.
BRD can lead to treatment costs, reduced weight gain, longer finishing periods, increased mortality risk and poorer production efficiency. The appropriate response is therefore not simply to select an antimicrobial; it is to reduce the conditions that allow disease to develop and spread.
Antimicrobial stewardship is central to the label
The Pradalex label states that use should be limited to treatment of BRD in cattle and swine respiratory disease in swine only after considering other non-fluoroquinolone therapeutic options. It also states that federal law prohibits extra-label use of the drug in food-producing animals. Source: DailyMed.
Fluoroquinolones are an important antimicrobial class, and unnecessary exposure can contribute to antimicrobial-resistance pressure. Veterinary prescribing decisions should be based on the approved label, clinical assessment, applicable veterinary oversight and the need to preserve antimicrobial effectiveness.
A seasonal article about BRD treatment must not be interpreted as a recommendation to use antibiotics preventively in all herds or to bypass veterinary diagnosis.
Practical winter BRD management
For cattle operations, a robust respiratory-health programme should integrate:
-
Appropriate ventilation and control of moisture and air quality.
-
Reduction of avoidable transport, mixing and handling stress.
-
Nutrition and water access that support animal resilience.
-
Vaccination and other preventive measures selected with the herd veterinarian.
-
Early recognition of respiratory signs and timely veterinary assessment.
-
Treatment protocols that specify when to treat, how to monitor response and when to reassess a non-responsive animal.
These measures help reduce disease pressure and support more judicious antimicrobial use.
Competitive implications for the animal-health industry
For Elanco, Pradalex sits within a broader livestock-health portfolio where efficacy, product availability, label clarity and veterinary confidence influence adoption. Competitors in BRD management compete across vaccines, diagnostics, antimicrobials, supportive care and herd-health services—not only within the injectable-antibiotic category.
The most defensible commercial proposition is a product embedded in a veterinary-led respiratory-health programme, rather than one positioned as a substitute for biosecurity or preventive management.
Conclusion
Pradalex offers a labelled antimicrobial option for specified BRD cases, but its use is constrained by animal-class restrictions and explicit stewardship requirements. With winter management challenges approaching, the industry’s priority should remain early diagnosis, herd-level prevention and responsible treatment.
